Evommune (EVMN) Shares Outstanding (Weighted Average) (2024 - 2026)

Evommune (EVMN) has 3 years of Shares Outstanding (Weighted Average) data on file, last reported at $33.7 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $33.7 million, up 2093.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.7 million (up 2093.54% YoY), and the FY2025 annual result was $6.1 million, up 306.86% from the prior year.
• Shares Outstanding (Weighted Average) rose to $33.7 million in Q1 2026 per EVMN's latest filing, from $6.1 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $33.7 million in Q1 2026 and troughed at $1.5 million in Q4 2024.
• A 3-year average of $7.7 million and a median of $1.5 million in 2025 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Weighted Average) advanced 1.28% in 2025, then surged 2093.54% in 2026.
• A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $1.5 million in 2024, then jumped by 306.86% to $6.1 million in 2025, then jumped by 448.67% to $33.7 million in 2026.
• Business Quant data shows EVMN's Shares Outstanding (Weighted Average) at $33.7 million in Q1 2026, $6.1 million in Q4 2025, and $1.5 million in Q3 2025.